Infinitopes

Infinitopes is a comprehensive cancer biotechnology company on the verge of entering the clinical stage, supported by Cancer Research UK (CRUK) and the University of Oxford. The company combines two world-leading platforms—precise antigen discovery and an efficient vector delivery system—to develop durable immune vaccines for various solid tumor indications. The lead vaccine candidate is expected to enter Phase I/IIa trials in the third quarter of 2024. Infinitopes has cultivated in-house expertise in antigen discovery, immunology, vaccinology, oncology, biomanufacturing, clinical trials, and regulatory affairs, and was awarded the Innovative Licensing and Access Pathway (ILAP) Innovation Passport by the UK Medicines and Healthcare products Regulatory Agency (MHRA) in 2022.